ArticleJournal of clinical laboratory analysis2025
A Set of Rapid Diagnostic Tool for Babesia microti Infection.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHuman babesiosis caused by Babesia microti is an emerging tick-borne zoonosis, with a global pooled prevalence of 2.23% and regional peaks in Europe (4.17%) and North America (1.54%). Traditional diagnostics like microscopy and polymerase chain reaction (PCR) suffer from low sensitivity in low-parasitemia cases or high costs ($230/test), necessitating accessible, rapid assays for resource-limited regions.
methodsA cross-priming amplification combined with vertical flow visualization (CPA-VF) assay, a straightforward molecular method targeting the 18S rRNA gene of B. microti, requires minimal equipment and facilitates rapid detection.
resultsSensitivity/Specificity: The CPA-VF assay detected 2.56 fg/reaction (equivalent to 0.000004% parasitic red blood cells), with a sensitivity of 95.5% matching that of RT-PCR but at a 60-fold lower cost ($3.8/test). It showed no cross-reactivity with B. duncani, B. divergens, or Plasmodium. Clinical Validation: Testing 49 positive samples (19 experimentally infected mice +30 artificially spiked) and 492 field samples, CPA-VF demonstrated 95.5% sensitivity (95% CI: 88.2-98.7) and 95.5% specificity compared to nested PCR (nPCR). Intra-assay coefficients of variation (CV) was 2.1%-7.2% and inter-assay kappa coefficient was 0.94, confirming reliability.
conclusionCPA-VF is a rapid, low-cost ($3.8/test), and instrument-free diagnostic tool for B. microti, particularly suitable for endemic regions where timely diagnosis reduces mortality risks from misdiagnosis as malaria. Its portability and visual readout address critical gaps in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.